Skip to Content

Robust survival outcome in HER2 positive metastatic breast cancer

Hear Shanu Modi, Memorial Sloan Kettering Cancer Center, New York, presents the updated results of treatment with trastuzumab deruxtecan in patients with HER2 positive metastatic breast cancer.

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top